Lyka Labs Limited has announced a board meeting scheduled for Tuesday, March 31, 2026, to address important business matters. The company has formally notified both stock exchanges about this upcoming meeting in compliance with regulatory requirements.

Meeting Details and Agenda

The board meeting has been scheduled with specific agenda items that require board approval and consideration. The primary focus of the meeting will be on addressing staffing requirements in the cost accounting function.

Key Business Items

The board will consider and transact the following specific business matters during the meeting:

• Cost Accountant Appointment: The board will approve and appoint Cost Accountants to fill the casual vacancy for the Financial Year 2025-26
• Remuneration Determination: The board will fix the remuneration for the appointed Cost Accountants
• Additional Business: Any other business matters that may arise during the meeting

Regulatory Compliance

Lyka Labs Limited has issued this intimation in accordance with Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has formally notified both BSE Limited and National Stock Exchange of India Limited about the scheduled board meeting.

The meeting information has also been made available on the company's official website at www.lykalabs.com for stakeholder access and transparency. Company Secretary and Compliance Officer Shailendra Kumar Agrawal signed the formal notification on March 23, 2026.

Lyka Labs has received approval from the National Company Law Tribunal (NCLT), Ahmedabad Bench for its scheme of amalgamation with Lyka Exports Limited. The tribunal sanctioned the merger on 16th March, 2026, marking a significant corporate restructuring milestone for the pharmaceutical company.

NCLT Approval Details

The NCLT approved the scheme of merger under sections 230-232 of the Companies Act, 2013, with Lyka Exports Limited serving as the transferor company and Lyka Labs Limited as the transferee company. The appointed date for the scheme has been set as April 01, 2022.

Regulatory Compliance and Stakeholder Approval

The merger received comprehensive regulatory scrutiny before approval. The tribunal had earlier directed stakeholder meetings on 23rd January, 2025, requiring separate meetings for equity shareholders and unsecured creditors of the transferor company, and meetings for equity shareholders, preference shareholders, secured creditors and unsecured creditors of the transferee company.

Chairman reports dated 05th March, 2025 confirmed successful completion of these meetings held on 04th March, 2025, with requisite approvals obtained from all stakeholder categories.

Key Regulatory Observations and Responses

The Regional Director and Registrar of Companies raised several observations during the review process:

Financial and Compliance Matters:

• One compliance issue involving Rs. 4,40,000/- interim compensation matter pending before Bombay High Court
• Outstanding income tax dues of Rs. 46,98,220/- for 2023-24, with rectification application filed
• Secured creditors valued at Rs. 17,39,86,563/- as of the review date

Stock Exchange Requirements:

• Lyka Labs' equity shares are listed on BSE and NSE
• Company provided timely intimations and disclosures to both exchanges
• No adverse observations received from either stock exchange

Implementation Timeline and Requirements

Following the NCLT approval, Lyka Labs must complete several statutory requirements:

• File e-form INC-28 with Registrar of Companies within 30 days
• Submit certified copy of order and scheme for registration
• Lodge order copy with Superintendent of Stamps for stamp duty adjudication within 60 days
• Pay Rs. 50,000/- as legal fees to Regional Director
• Pay Rs. 20,000/- as Official Liquidator fees

Corporate Structure Impact

Upon implementation, Lyka Exports Limited will be dissolved without winding up, with all assets, liabilities, and operations transferring to Lyka Labs Limited. All employees of the transferor company will become employees of Lyka Labs with continuity of service and no less favorable terms and conditions.

The tribunal emphasized that the approval does not grant exemption from stamp duty, taxes, or other regulatory compliance requirements. All statutory obligations under various laws including Income Tax Act, GST, and FEMA remain applicable to the merged entity.